Chondrocalcinosis and Hypomagnesemia: Clinical and Radiological Progression

José González Domínguez, Alejandro Escudero Contreras, Verónica Pérez Guijo, Francisco Ginés Martínez Sánchez, Miguel Ángel Caracuel Ruiz, and Eduardo Collantes Estévez

Introduction

Hypomagnesemia can be among the secondary causes of joint chondrocalcinosis (JCC), which can be the cause of its pathogenesis.

Its early diagnosis is very important because, upon ionic correction of the hypomagnesemia, clinical, and radiological progression of JCC can be avoided.

In the present study we describe the clinical and radiological progression of 2 young patients with repeated bouts of acute monoarthritis with JCC and hypomagnesemia.

Clinical Cases

Case 1

A 40-year-old male patient presented his first episode of monoarthritis at 26 years of age on the right knee and afterward, until he was 35, was attended by our department and had presented 3 bouts of acute monoarthritis. Upon visiting our outpatient clinic, the patient was treated for an episode of right knee monoarthritis and underwent arthrocentesis and received a steroid infiltration. Radiologically, he was diagnosed with JCC of both knees, mainly the righ one, with a discreet impingement of the internal femorotibial joint line. No JCC was detected either on the wrist or the pubic symphysis.
A complete analysis included: complete hemogram, erythrocyte sedimentation rate (ESR), CRP, blood chemistry (glucose, urea, creatinine, Na, K, Cl, Ca, P, AST, ALT, GGT, alkaline phosphatase, creatin kinase [CPK], lactatedehydrogenase [LDH], uricemia, total cholesterol, triglycerides), and all were normal, except cholesterol, 233 mg/dL (normal value, 220 mg/dL) and magnesemia, 1.4 mg/dL (normal value, >1.8 mg/dL). Urine test and sediment, also normal; T4 and thyrotropin (TSH), normal; parathyroid hormone, normal.

The patient was treated with non-steroidal antiinflammatory drugs (NSAID) (in the acute stage of the disease) and continuously with magnesium at a dose of 1 g/day (with an equivalence to 94.8 mg of Mg ion) and colchicine 0.6 mg/day for 1 year. After the start of treatment with magnesium, the patient has not had any more recurrences of acute monoarthritis; he is still asymptomatic although occasionally he has moderate pain on the knees. In posterior analytical controls the patient maintained magnesium levels between 1.7 and 1.8 mg/dL. On the knees, and after 5 years of disease, there was progression of the radiologic lesions (Figures 1 and 2). Additionally, an x-ray family study was carried out on the patients living first degree relatives: his mother, 2 sisters (35 and 32 years old, respectively), and a brother (27 years old), only detecting JCC in his mother.

Case 2

A 43-year-old patient who was treated in our outpatient clinic at 39 years of age was sent by the emergency department due to acute monoarthritis of the right knee; in the previous 2 months he had presented 2 bouts of monoarthritis. Radiologically, his knees presented JCC in the femorotibial compartment of his right knee. There were no valuable signs in the pelvis x-ray and carpal bones. Complementary analysis included: a complete hemogram, ESR, CRP, blood chemistry (glucose, urea, creatinine, Na, K, Cl, Mg, Ca, P, AST, ALT, GGT, alkaline phosphatase, CPK, LDH, uricemia, total cholesterol, triglycerides) which were normal, except CRP, 10 (normal, 8); serum magnesium, 1.6 mg/dL, (normal, >1.8 mg/dL). Rheumatoid factor was negative. Urine testing and sediment were normal. T4 and TSH, normals. Urinary calcium and phosphate were normal.

After 1 year of treatment with magnesium 1 g/day and colchicine 0.6 mg/day, the patient presented a relapse of arthritis of the elbows and the right wrist, with a serum magnesium level of 1.6 mg/dL. X-rays of the hands, feet, and elbows showed no valuable findings. The episode was resolved after a few days of anti-inflammatory treatment and did not present again.

During these years, the patient has received magnesium supplements with regularity and has been clinically asymptomatic. The radiological aspect of his knees has been unchanged but the calcified tissue has not disappeared (JCC) from the right knee. He has no other family members who are affected.

Discussion

Hypomagnesemia has been associated to calcium pyrophosphate crystal deposit disease (CPPD), which is one of the secondary causes of JCC. Magnesium is known to be one of the cofactors of many pyrophosphatases and there is a direct relationship between the solubility of the calcium pyrophosphatase and the serum...
Hypomagnesemia can produce crystal deposition disease (CPPD) due to the pyrophosphates’ enzymatic activity dependence on Mg ions. Precipitation of these CPPD crystals in the joint produces episodes of pseudogout similar to the ones described in our patients. Occasionally, chondrocalcinosis and hypomagnesemia have been associated to Bartter’s syndrome (BS), which is characterized by hypokalemia, metabolic alkalosis, hyperaldosteronism, and renal loss of chloride and potassium, indicating a defect in chloride reabsorption in the ascending segment of Henle’s loop. CPPD deposit disease and hypomagnesemia have also been associated to a hereditary variant of hypocalciuric BS known as Gitelman’s syndrome (GS) and characterized by hypokalemia and hypomagnesemia of a renal origin next to hypocalciuria.

Several causes for idiopathic familial and secondary JCC have been described. The prevalence of the primary familial crystal CPPD deposit disease associated to endocrine or metabolic illnesses is unknown. A study carried out in Spain revealed that an elevated proportion of sporadic cases of CPPD crystal deposit disease can have a familial origin. In most of the patients CPPD crystal deposit disease presents itself as an idiopathic or sporadic form, and there occasionally can be found a rare familial form associated to certain metabolic alterations among which hyperparathyroidism, hemochromatosis, hypophosphatemia, and hypomagnesemia can be included. There are 2 clinical forms of CPPD crystal deposit disease. One of them is relatively benign, starts at an early age (patients are usually younger than 50 years old), and is characterized by polyarticular affection (knees, wrists, shoulders, elbows, and hips) with recurrent episodes of pseudogout and JCC, and scarce, or non-existent joint deformity. The second form of presentation is more destructive, starts later in life (patients are older than 50), and is manifested as oligoarthritis that can affect knees, wrists, shoulders, and hips, developing progressive and deforming arthropathy (chronic pyrophosphate arthropathy). We have described 2 cases of secondary chondrocalcinosis associated with hypomagnesemia in young patients who presented several bouts of acute monoarthritis of the knees and in whom a low level of magnesium was shown and whom, after treatment was started with magnesium supplementation, have not presented any new episodes of arthritis in their course over the past 4 years. In our patients, the values of Na, K, Cl, Ca, and P were normal, considering that the patients were not affected by either BS or its variant (SG). It is important to mention that, in the first case described, a familial association was shown, with the patients mother also presenting with chondrocalcinosis of the knees. In addition, the patient presented his first bout of monoarthritis at a young age, 26 years. In this patient, in spite of staying asymptomatic after the start of supplementation with magnesium, an unfavorable radiologic progression was seen on his knees.

This patient developed a degenerative arthropathy of the knees, in spite of early development of disease, in direct contrast with the second familial clinical form of JCC which starts later in life. These facts indicate that, in the patients with familial chondrocalcinosis and hypomagnesemia, joint deterioration is larger than in patients with idiopathic JCC and hypomagnesemia. In the patients with familial JCC, magnesium supplementation seems to limit the episodic nature of the bouts of arthritis, but do not stop the radiologic deterioration. Due to all of this, we reiterate the convenience of a determination of serum ions that includes magnesium, especially in young patients with JCC and, if possible, the performance of a family study.

References